A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms
Angelika Wagner, Angela Guzek, Johanna Ruff, Joanna Jasinska, Ute Scheikl, Ines Zwazl, Michael Kundi, Hannes Stockinger, Maria R. Farcet, Thomas R. Kreil, Eva Hoeltl, Ursula Wiedermann
doi: https://doi.org/10.1101/2020.12.22.20248604
Angelika Wagner
1Institute of Specific Prophylaxis and Tropical Medicine, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Angela Guzek
1Institute of Specific Prophylaxis and Tropical Medicine, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Johanna Ruff
1Institute of Specific Prophylaxis and Tropical Medicine, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Joanna Jasinska
1Institute of Specific Prophylaxis and Tropical Medicine, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Ute Scheikl
1Institute of Specific Prophylaxis and Tropical Medicine, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Ines Zwazl
1Institute of Specific Prophylaxis and Tropical Medicine, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Michael Kundi
2Centre for Public Health, Medical University of Vienna, Vienna, Austria
Hannes Stockinger
3Institute for Hygiene and Applied Immunology, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Maria R. Farcet
4Global Pathogen Safety, Baxter AG, a Takeda company, Vienna, Austria
Thomas R. Kreil
4Global Pathogen Safety, Baxter AG, a Takeda company, Vienna, Austria
Eva Hoeltl
5Health Centre Erste Bank, Erste Bank, Vienna, Austria
Ursula Wiedermann
1Institute of Specific Prophylaxis and Tropical Medicine, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Article usage
Posted December 22, 2020.
A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms
Angelika Wagner, Angela Guzek, Johanna Ruff, Joanna Jasinska, Ute Scheikl, Ines Zwazl, Michael Kundi, Hannes Stockinger, Maria R. Farcet, Thomas R. Kreil, Eva Hoeltl, Ursula Wiedermann
medRxiv 2020.12.22.20248604; doi: https://doi.org/10.1101/2020.12.22.20248604
A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms
Angelika Wagner, Angela Guzek, Johanna Ruff, Joanna Jasinska, Ute Scheikl, Ines Zwazl, Michael Kundi, Hannes Stockinger, Maria R. Farcet, Thomas R. Kreil, Eva Hoeltl, Ursula Wiedermann
medRxiv 2020.12.22.20248604; doi: https://doi.org/10.1101/2020.12.22.20248604
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2595)
- Dermatology (218)
- Emergency Medicine (390)
- Epidemiology (12132)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4026)
- Geriatric Medicine (378)
- Health Economics (670)
- Health Informatics (2604)
- Health Policy (994)
- Hematology (358)
- HIV/AIDS (830)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3794)
- Nursing (208)
- Nutrition (561)
- Oncology (1986)
- Ophthalmology (576)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (248)
- Palliative Medicine (72)
- Pathology (470)
- Pediatrics (1097)
- Primary Care Research (443)
- Public and Global Health (6467)
- Radiology and Imaging (1375)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (336)
- Surgery (437)
- Toxicology (51)
- Transplantation (185)
- Urology (165)